Skip to main content



Page 1 of 34

  1. Content type: Original investigation

    Cardiovascular outcome trials have documented a strong benefit of sodium glucose cotransporter-2 inhibitors (SGLT2i) on the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D)...

    Authors: Benedetta Maria Bonora, Saula Vigili de Kreutzenberg, Angelo Avogaro and Gian Paolo Fadini

    Citation: Cardiovascular Diabetology 2019 18:106

    Published on:

  2. Content type: Original investigation

    Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. The purpose of this study was to asses...

    Authors: Zengliang Wang, Bo Li, Yongxin Wang, Aisha Maimaitili, Hu Qin, Geng Dangmurenjiafu and Shuo Wang

    Citation: Cardiovascular Diabetology 2019 18:105

    Published on:

  3. Content type: Original investigation

    To examine the effect of high-intensity interval training (HIIT) on metabolic syndrome (MetS) and body composition in cardiac rehabilitation (CR) patients with myocardial infarction (MI).

    Authors: Yaoshan Dun, Randal J. Thomas, Joshua R. Smith, Jose R. Medina-Inojosa, Ray W. Squires, Amanda R. Bonikowske, Hsuhang Huang, Suixin Liu and Thomas P. Olson

    Citation: Cardiovascular Diabetology 2019 18:104

    Published on:

  4. Content type: Original investigation

    We investigated the association regarding severe hypoglycemia episodes with cardiovascular disease risk and all-cause mortality in patients with type 2 diabetes.

    Authors: Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Seon-Ah Cha, Yu-Bae Ahn and Seung-Hyun Ko

    Citation: Cardiovascular Diabetology 2019 18:103

    Published on:

  5. Content type: Original investigation

    Myocardial infarction is the main mortality cause in patients with type 2 diabetes (T2DM). Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step of atherogenesis. Asymmet...

    Authors: Gaia Chiara Mannino, Serena Pezzilli, Carolina Averta, Anastasia Fuoco, Rosangela Spiga, Elettra Mancuso, Concetta Di Fatta, Francesco Perticone, Sabrina Prudente, Vincenzo Trischitta, Francesco Andreozzi and Giorgio Sesti

    Citation: Cardiovascular Diabetology 2019 18:102

    Published on:

  6. Content type: Correction

    Following publication of the original article [1], the authors reported an error in Fig. 3. The bars in the upper right panel that represent heart rate in placebo treated patients is not correct.

    Authors: Maurice B. Bizino, Ingrid M. Jazet, Jos J. M. Westenberg, Huub J. van Eyk, Elisabeth H. M. Paiman, Jan W. A. Smit and Hildebrandus J. Lamb

    Citation: Cardiovascular Diabetology 2019 18:101

    Published on:

    The original article was published in Cardiovascular Diabetology 2019 18:55

  7. Content type: Original investigation

    Adverse cardiac remodeling after ST-segment elevation myocardial infarction (STEMI) is a major cause for poor cardiovascular outcomes such as heart failure. The predisposing factors and underlying mechanisms r...

    Authors: Chen Die Yang, Ying Shen, Lin Lu, Feng Hua Ding, Zhen Kun Yang, Rui Yan Zhang, Wei Feng Shen, Wei Jin and Xiao Qun Wang

    Citation: Cardiovascular Diabetology 2019 18:100

    Published on:

  8. Content type: Review

    To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Pr...

    Authors: Aaron Y. Kluger, Kristen M. Tecson, Andy Y. Lee, Edgar V. Lerma, Janani Rangaswami, Norman E. Lepor, Michael E. Cobble and Peter A. McCullough

    Citation: Cardiovascular Diabetology 2019 18:99

    Published on:

  9. Content type: Original investigation

    Large changes in health behaviors achieved through intensive lifestyle intervention programs improve cardiovascular disease (CVD) risk factors among adults with type 2 diabetes. However, such interventions are...

    Authors: Jean Strelitz, Amy L. Ahern, Gráinne H. Long, Clare E. Boothby, Nicholas J. Wareham and Simon J. Griffin

    Citation: Cardiovascular Diabetology 2019 18:98

    Published on:

  10. Content type: Original investigation

    Associations between sex hormones and vascular remodeling have been extensively studied, but the results vary widely among different races and sex. We aimed to investigate whether total testosterone (TT), estr...

    Authors: Chiyu Wang, Wen Zhang, Yuying Wang, Heng Wan, Yi Chen, Fangzhen Xia, Kun Zhang, Ningjian Wang and Yingli Lu

    Citation: Cardiovascular Diabetology 2019 18:97

    Published on:

  11. Content type: Original investigation

    Metformin is the most widely prescribed drug to lower glucose and has a definitive effect on the cardiovascular system. The goal of this systematic review and meta-analysis is to assess the effects of metformi...

    Authors: Yechen Han, Hongzhi Xie, Yongtai Liu, Peng Gao, Xufei Yang and Zhujun Shen

    Citation: Cardiovascular Diabetology 2019 18:96

    Published on:

  12. Content type: Original investigation

    It has been reported that the triglyceride-glucose (TyG) index may serve as a simple and credible surrogate marker of insulin resistance (IR). However, its association with macrovascular and microvascular dama...

    Authors: Song Zhao, Shikai Yu, Chen Chi, Ximin Fan, Jiamin Tang, Hongwei Ji, Jiadela Teliewubai, Yi Zhang and Yawei Xu

    Citation: Cardiovascular Diabetology 2019 18:95

    Published on:

  13. Content type: Commentary

    The definition of class effect for SGLT-2 inhibitors may be based on three concepts: a similar chemical structure, a similar mechanism of action and similar pharmacological effects. We have also assumed that a...

    Authors: Dario Giugliano and Katherine Esposito

    Citation: Cardiovascular Diabetology 2019 18:94

    Published on:

  14. Content type: Original investigation

    Individuals with diabetes have remarkably high rates of cardiovascular morbidity and mortality. However, the incremental cardiovascular risk in diabetes is heterogeneous and has often been related to renal inv...

    Authors: Ana Palanca, Esmeralda Castelblanco, Àngels Betriu, Hèctor Perpiñán, Berta Soldevila, José Manuel Valdivielso, Marcelino Bermúdez-Lopez, Carlos Puig-Jové, Manel Puig-Domingo, Per-Henrik Groop, Elvira Fernández, Núria Alonso and Didac Mauricio

    Citation: Cardiovascular Diabetology 2019 18:93

    Published on:

  15. Content type: Original investigation

    Degenerative aortic stenosis (AS), a disease of the elderly, frequently coexists with concomitant diseases, including type 2 diabetes (T2DM) which amplifies the cardiovascular (CV) risk. T2DM affects left vent...

    Authors: Ewa Czestkowska, Agnieszka Rożanowska, Dorota Długosz, Klaudiusz Bolt, Jolanta Świerszcz, Olga Kruszelnicka, Bernadeta Chyrchel and Andrzej Surdacki

    Citation: Cardiovascular Diabetology 2019 18:92

    Published on:

  16. Content type: Original investigation

    Glucagon-like peptide-1 (GLP-1) treatment has been shown to reduce stroke incidence in diabetes and also to be neuroprotective in experimental stroke models. The prognostic value of endogenous levels of GLP-1 ...

    Authors: Martin Larsson, Cesare Patrone, Mia von Euler, Jens J. Holst and David Nathanson

    Citation: Cardiovascular Diabetology 2019 18:91

    Published on:

  17. Content type: Original investigation

    Experimental and clinical data indicate a major influence of diabetes on atherogenesis. We aimed to assess whether the effect of diabetes on long-term mortality in asymptomatic patient with carotid stenosis is...

    Authors: Matthias Hoke, Martin Schillinger, Erich Minar, Georg Goliasch, Christoph J. Binder and Florian J. Mayer

    Citation: Cardiovascular Diabetology 2019 18:90

    Published on:

  18. Content type: Original investigation

    The triglyceride-glucose index (TyG index) is a tool for insulin resistance evaluation, however, little is known about its association with coronary artery disease (CAD), which is the major cardiovascular deat...

    Authors: Alessandra da Silva, Ana Paula Silva Caldas, Helen Hermana Miranda Hermsdorff, Ângela Cristine Bersch-Ferreira, Camila Ragne Torreglosa, Bernardete Weber and Josefina Bressan

    Citation: Cardiovascular Diabetology 2019 18:89

    Published on:

  19. Content type: Original investigation

    Hypertension is one of the strongest risk factors for stroke in the general population, while systolic blood pressure has been shown to independently increase the risk of stroke in type 1 diabetes. The aim of ...

    Authors: Stefanie Hägg-Holmberg, Emma H. Dahlström, Carol M. Forsblom, Valma Harjutsalo, Ron Liebkind, Jukka Putaala, Turgut Tatlisumak, Per-Henrik Groop and Lena M. Thorn

    Citation: Cardiovascular Diabetology 2019 18:88

    Published on:

  20. Content type: Original investigation

    South Asians have a high risk to develop type 2 diabetes, which may be related to substantial ectopic fat deposition. Since glucagon-like peptide-1 analogues can reduce ectopic fat accumulation, the aim of the...

    Authors: Huub J. van Eyk, Elisabeth H. M. Paiman, Maurice B. Bizino, Paul de Heer, Petronella H. Geelhoed-Duijvestijn, Aan V. Kharagjitsingh, Johannes W. A. Smit, Hildo J. Lamb, Patrick C. N. Rensen and Ingrid M. Jazet

    Citation: Cardiovascular Diabetology 2019 18:87

    Published on:

  21. Content type: Original investigation

    Branched chain amino acids (BCAA) can impair insulin signaling, and cardiac insulin resistance can occur in the failing heart. We, therefore, determined if cardiac BCAA accumulation occurs in patients with dil...

    Authors: Golam M. Uddin, Liyan Zhang, Saumya Shah, Arata Fukushima, Cory S. Wagg, Keshav Gopal, Rami Al Batran, Simran Pherwani, Kim L. Ho, Jamie Boisvenue, Qutuba G. Karwi, Tariq Altamimi, David S. Wishart, Jason R. B. Dyck, John R. Ussher, Gavin Y. Oudit…

    Citation: Cardiovascular Diabetology 2019 18:86

    Published on:

  22. Content type: Original investigation

    Recent large-scale clinical trials have shown that SGLT2-inhibitors reduce cardiovascular events in diabetic patients. However, the regulation and functional role of cardiac sodium–glucose cotransporter (SGLT1...

    Authors: Akira Yoshii, Tomohisa Nagoshi, Yusuke Kashiwagi, Haruka Kimura, Yoshiro Tanaka, Yuhei Oi, Keiichi Ito, Takuya Yoshino, Toshikazu D. Tanaka and Michihiro Yoshimura

    Citation: Cardiovascular Diabetology 2019 18:85

    Published on:

  23. Content type: Review

    Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medi...

    Authors: Omar Sheikh, Anthony G. Vande Hei, Ayman Battisha, Tarek Hammad, Son Pham and Robert Chilton

    Citation: Cardiovascular Diabetology 2019 18:84

    Published on:

  24. Content type: Original investigation

    Perivascular adipose tissue (PVAT) plays a critical role in the pathogenesis of cardiovascular disease. It is unclear whether inhibition of sodium glucose cotransporter 2 (SGLT2) in subjects with type 2 diabet...

    Authors: Kentaro Mori, Kyoichiro Tsuchiya, Suguru Nakamura, Yasutaka Miyachi, Kumiko Shiba, Yoshihiro Ogawa and Kenichiro Kitamura

    Citation: Cardiovascular Diabetology 2019 18:83

    Published on:

  25. Content type: Original investigation

    We investigated whether or to what extent the interaction of lipoprotein (a) [Lp(a)] with cholesterol-containing lipids was associated with angiographic coronary collateralization in type 2 diabetic patients w...

    Authors: Ying Shen, Shuai Chen, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Zhen Kun Yang, Jian Hu, Lin Lu, Feng Hua Ding and Wei Feng Shen

    Citation: Cardiovascular Diabetology 2019 18:82

    Published on:

  26. Content type: Original investigation

    In patients with diabetes, death and cardiovascular diseases are attributed to classical risk factors such as hypertension, dyslipidemia, and smoking habit, whereas these events are attributed to frailty in th...

    Authors: Satoshi Ida, Ryutaro Kaneko, Kanako Imataka and Kazuya Murata

    Citation: Cardiovascular Diabetology 2019 18:81

    Published on:

  27. Content type: Review

    Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, res...

    Authors: Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil and Ashok Jaiswal

    Citation: Cardiovascular Diabetology 2019 18:80

    Published on:

  28. Content type: Original investigation

    Prevalent diabetes at the time of heart failure (HF) diagnosis is associated with a higher risk of death, but the incidence and prognostic importance of new-onset diabetes in patients with established HF remai...

    Authors: B. Zareini, Rasmus Rørth, Anders Holt, Ulrik M. Mogensen, Christian Selmer, Gunnar Gislason, Morten Schou, Lars Køber, Christian Torp-Pedersen, Morten Lamberts and Søren Lund Kristensen

    Citation: Cardiovascular Diabetology 2019 18:79

    Published on:

  29. Content type: Original investigation

    Diabetes mellitus is a chronic disease that impacts an increasing percentage of people each year. Among its comorbidities, diabetics are two to four times more likely to develop cardiovascular diseases. While ...

    Authors: Quincy A. Hathaway, Skyler M. Roth, Mark V. Pinti, Daniel C. Sprando, Amina Kunovac, Andrya J. Durr, Chris C. Cook, Garrett K. Fink, Tristen B. Cheuvront, Jasmine H. Grossman, Ghadah A. Aljahli, Andrew D. Taylor, Andrew P. Giromini, Jessica L. Allen and John M. Hollander

    Citation: Cardiovascular Diabetology 2019 18:78

    Published on:

  30. Content type: Original investigation

    Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE). The contribution of ticagrelor, a P2Y12 antag...

    Authors: Robert S. Rosenson, Qinzhong Chen, Sherwin D. Najera, Prakash Krishnan, Martin L. Lee and Daniel J. Cho

    Citation: Cardiovascular Diabetology 2019 18:77

    Published on:

  31. Content type: Original investigation

    The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high C...

    Authors: Lawrence A. Leiter, Stephen C. Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, Theis Gondolf, Thomas Hansen, Ingrid Holst and Ildiko Lingvay

    Citation: Cardiovascular Diabetology 2019 18:73

    Published on:

  32. Content type: Original investigation

    Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin...

    Authors: Akira Sezai, Hisakuni Sekino, Satoshi Unosawa, Makoto Taoka, Shunji Osaka and Masashi Tanaka

    Citation: Cardiovascular Diabetology 2019 18:76

    Published on:

  33. Content type: Original investigation

    To examine whether glycemic control of gestational diabetes mellitus (GDM) could modify the risk for future maternal metabolic and cardiovascular morbidities.

    Authors: Enav Yefet, Naama Schwartz, Basma Sliman, Avraham Ishay and Zohar Nachum

    Citation: Cardiovascular Diabetology 2019 18:75

    Published on:

  34. Content type: Original investigation

    Type-2 diabetes mellitus is one of the major risk factors of atherosclerosis, particularly in peripheral artery disease (PAD). Several studies have documented a correlation between omentin-1 serum levels, athe...

    Authors: Federico Biscetti, Elisabetta Nardella, Nicola Bonadia, Flavia Angelini, Dario Pitocco, Angelo Santoliquido, Marco Filipponi, Raffaele Landolfi and Andrea Flex

    Citation: Cardiovascular Diabetology 2019 18:74

    Published on:

  35. Content type: Original investigation

    The global burden of type 2 diabetes mellitus (T2DM), together with the presence of cardiovascular risk in this population, is reaching pandemic levels. A prominent feature of T2DM is chronic and systemic infl...

    Authors: Shehan N. Randeria, Greig J. A. Thomson, Theo A. Nell, Timothy Roberts and Etheresia Pretorius

    Citation: Cardiovascular Diabetology 2019 18:72

    Published on:

  36. Content type: Review

    In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events...

    Authors: Jean-Charles Fruchart, Raul D. Santos, Carlos Aguilar-Salinas, Masanori Aikawa, Khalid Al Rasadi, Pierre Amarenco, Philip J. Barter, Richard Ceska, Alberto Corsini, Jean-Pierre Després, Patrick Duriez, Robert H. Eckel, Marat V. Ezhov, Michel Farnier, Henry N. Ginsberg, Michel P. Hermans…

    Citation: Cardiovascular Diabetology 2019 18:71

    Published on:

  37. Content type: Review

    The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovasc...

    Authors: Samuel Seidu, Setor K. Kunutsor, Howard D. Sesso, J. M. Gaziano, J. E. Buring, Maria Carla Roncaglioni and Kamlesh Khunti

    Citation: Cardiovascular Diabetology 2019 18:70

    Published on:

  38. Content type: Original investigation

    A low 1,5-anhydro-d-glucitol (AG) blood level is considered a clinical marker of postprandial hyperglycemia. Previous studies reported that 1,5-AG levels were associated with vascular endothelial dysfunction and ...

    Authors: Hideki Wada, Tomotaka Dohi, Katsumi Miyauchi, Norihito Takahashi, Hirohisa Endo, Yoshiteru Kato, Manabu Ogita, Iwao Okai, Hiroshi Iwata, Shinya Okazaki, Kikuo Isoda, Kazunori Shimada, Satoru Suwa and Hiroyuki Daida

    Citation: Cardiovascular Diabetology 2019 18:69

    Published on:

  39. Content type: Original investigation

    Hyperglycemia has detrimental effect on ischemic myocardium, but the impact of acute hyperglycemia on the myocardium in asymptomatic diabetic patients has not been fully elucidated. Thus, this follow-up study ...

    Authors: Jelena Bogdanović, Milika Ašanin, Gordana Krljanac, Nebojša M. Lalić, Aleksandra Jotić, Sanja Stanković, Nataša Rajković, Ljubica Stošić, Iva Rasulić, Jelena Milin, Dragana Popović, Ljiljana Bogdanović and Katarina Lalić

    Citation: Cardiovascular Diabetology 2019 18:68

    Published on:

  40. Content type: Original investigation

    Pioglitazone is an oral antidiabetic drug with multiple pleiotropic actions. Recent clinical trials have demonstrated that treatment with pioglitazone reduces cardiovascular risk in patients who have had an is...

    Authors: Min-Hee Woo, Hye Sun Lee and Jinkwon Kim

    Citation: Cardiovascular Diabetology 2019 18:67

    Published on:

  41. Content type: Original investigation

    The mechanisms underlying increased mortality in patients with diabetes and admission hyperglycemia after an acute coronary syndrome may involve reduced capacity for cardioprotection. We investigated the impac...

    Authors: Steen Buus Kristiansen, Kim Bolther Pælestik, Jacob Johnsen, Nichlas Riise Jespersen, Kasper Pryds, Marie Vognstoft Hjortbak, Rebekka Vibjerg Jensen and Hans Erik Bøtker

    Citation: Cardiovascular Diabetology 2019 18:66

    Published on:

  42. Content type: Original investigation

    Haptoglobin (Hp) is an abundant plasma protein with anti-oxidant properties. Hp polymorphism is associated with cardio-metabolic dysfunction but the allele conferring risk of developing acute myocardial infarc...

    Authors: Resham L. Gurung, M. Yiamunaa, Sylvia Liu, Jian Jun Liu, Clara Chan, Robin Wai Munn Choo, Keven Ang, Chee Fang Sum, Subramaniam Tavintharan and Su Chi Lim

    Citation: Cardiovascular Diabetology 2019 18:65

    Published on:

  43. Content type: Review

    Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 diabetes mellitus (T2DM). In the...

    Authors: Salvatore Carbone and Dave L. Dixon

    Citation: Cardiovascular Diabetology 2019 18:64

    Published on:

  44. Content type: Original investigation

    Diabetes mellitus (DM) on insulin is a patient-related factor in the assessment of surgical risk based on the EuroSCORE II and, as such, it confers additional risk on outcomes after transcatheter aortic valve ...

    Authors: Panagiotis Tzamalis, Valentin Herzberger, Jens Bergmann, Alexander Wuerth, Peter Bramlage, Holger Schroefel, Claus Schmitt and Gerhard Schymik

    Citation: Cardiovascular Diabetology 2019 18:63

    Published on:

  45. Content type: Original investigation

    Although microvascular dysfunction is known to result from diabetes, it might also lead to diabetes. Lower values of C2, a derivative of the radial artery pressure waveform, indicate microvascular dysfunction ...

    Authors: Daniel A. Duprez, Nkete I. Forbang, Matthew A. Allison, Carmen A. Peralta, Steven Shea and David R. Jacobs Jr.

    Citation: Cardiovascular Diabetology 2019 18:62

    Published on:

  46. Content type: Original investigation

    The relationship between dyslipidemia, inflammation and CV organ damage in type 2 diabetes mellitus (T2DM) is complex. Insulin resistance and inflammatory cytokines interleukins (ILs) increase plasma triglycer...

    Authors: Michaela Kozakova, Carmela Morizzo, Isabel Goncalves, Andrea Natali, Jan Nilsson and Carlo Palombo

    Citation: Cardiovascular Diabetology 2019 18:61

    Published on:

  47. Content type: Original investigation

    The main aims of this study were to examine the incidence and in-hospital outcomes of mechanical and bioprosthetic surgical mitral valve replacement (SMVR) among patients with and without T2DM.

    Authors: Ana López-de-Andrés, Javier de Miguel-Díez, Nuria Muñoz-Rivas, Valentín Hernández-Barrera, Manuel Méndez-Bailón, José M. de Miguel-Yanes and Rodrigo Jiménez-García

    Citation: Cardiovascular Diabetology 2019 18:60

    Published on:

  48. Content type: Original investigation

    The efficacy of ertugliflozin, a sodium–glucose cotransporter 2 inhibitor, for glycemic and blood pressure (BP) control has been demonstrated in phase 3 studies. To further evaluate the effects of ertugliflozi...

    Authors: Jie Liu, Annpey Pong, Silvina Gallo, Amanda Darekar and Steven G. Terra

    Citation: Cardiovascular Diabetology 2019 18:59

    Published on:

  49. Content type: Original investigation

    The aim was to assess coronary atherosclerosis, plaque morphology and associations to cardiovascular risk factors and epicardial adipose tissue (EAT) in patients with long duration of type 1 diabetes mellitus ...

    Authors: Mona Svanteson, Kristine Bech Holte, Ylva Haig, Nils Einar Kløw and Tore Julsrud Berg

    Citation: Cardiovascular Diabetology 2019 18:58

    Published on:

  50. Content type: Original investigation

    Dyslipidaemia has always been regarded as the cornerstone of arteriosclerosis and is related to the pathogenesis of renal insufficiency. However, it is unclear which routinely available lipid parameter is rela...

    Authors: Yu-Xia Wang, An-Ping Wang, Ying-Nan Ye, Zheng-Nan Gao, Xu-Lei Tang, Li Yan, Qin Wan, Wei-Qing Wang, Zuo-Jie Luo, Gui-Jun Qin, Lu-Lu Chen and Yi-Ming Mu

    Citation: Cardiovascular Diabetology 2019 18:57

    Published on:

Annual Journal Metrics